Online Program

326676
Adjusting for comorbidities in disease expenditure studies: An application to United States national inpatient data


Monday, November 2, 2015

Joseph Dieleman, PhD, Department of Global Health, University of Washington, Institute for Health Metrics and Evaluation, Seattle,, WA
Ranju Baral, PhD, Department of Global Health, University of Washington, Institute for Health Metrics and Evaluation, Seattle, WA
Maxwell Birger, BS, Department of Global Health, University of Washington, Institute for Health Metrics and Evaluation, Seattle, WA
Anthony Bui, BA, Department of Global Health, University of Washington, Institute for Health Metrics and Evaluation, Seattle, WA
Anne Bulchis, MPH, Department of Global Health, University of Washington, Institute for Health Metrics and Evaluation, Seattle, WA
Hannah Hamavid, BA, Department of Global Health, University of Washington, Institute for Health Metrics and Evaluation, Seattle, WA
Cody Horst, BS, Department of Global Health, University of Washington, Institute for Health Metrics and Evaluation, Seattle, WA
Elizabeth Johnson, BA, Department of Global Health, University of Washington, Institute for Health Metrics and Evaluation, Seattle, WA
Jonathan Joseph, BS, Department of Global Health, University of Washington, Institute for Health Metrics and Evaluation, Seattle, WA
Liya Lomsadze, BS, Department of Global Health, University of Washington, Institute for Health Metrics and Evaluation, Seattle, WA
Christopher Murray, MD, DPhil, Department of Global Health, University of Washington, Institute for Health Metrics and Evaluation, Seattle, WA
One of the major challenges in tracking health expenditure is allocating expenditure for a health care event to a single disease when comorbidities are present. Disease expenditure studies tend to ignore comorbidities although it is increasingly an issue, in part reflecting the epidemiologic transition from acute to chronic diseases. In this study, we propose a regression-based method for comorbidity adjustment, particularly relevant for a health system encounter-based approach. Encounter-based approaches assign expenditure to disease based on the coded diagnoses. Without comorbidity adjustment, the expenditure is assigned entirely to the primary diagnosis and the estimates are biased.

We apply this framework for comorbidity adjustment to the National Inpatient Survey data in the United States for years 1996-2010. For each disease, comorbidity adjustment factors are generated separately by age and sex. Our preliminary estimates suggest that mental health problems such as unipolar depressive disorders have the greatest increase in expenditure after adjustment, whereas dementia has the greatest decrease in expenditure after comorbidity adjustment.

Our methodology takes a unified approach to comorbidity, which not only accounts for excess expenditure that needs to be distributed away from a primary diagnosis, but also the inflows of expenditures that needs to be redistributed towards each disease acting as a comorbidity for other primary diagnoses. Correcting for comorbidities provides a more accurate estimates of the expenditure incurred by specific diseases.

Learning Areas:

Biostatistics, economics
Public health or related public policy
Social and behavioral sciences

Learning Objectives:
Describe an “encounter-based approach” for health expenditure tracking. Explain the rationale for comorbidity adjustment and the conceptual underpinnings of this particular method. List several diseases which increase expenditure after adjustment and some which decrease expenditure.

Keyword(s): Health Care Costs, Economic Analysis

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I have lead the Financial Resources of Health research team at the Institute for Health Metrics and Evaluation for two years, have worked in global health and health economics for five years, and have PhD in economics. I am co-investigator or co-principal investigator on several funded grants related to tracking resources for health.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.